No matter whether you are a seasoned programmer or you simply want to take your first steps in writing code, Repl.it wants to help you get from idea to result as fast as possible — without complicated ...
Replimune’s RP1+nivolumab melanoma BLA faces an FDA decision by Apr 10, 2026. The current cash runway extends to Q1'27. See ...
Repl.it is a start-up whose technology lets software engineers quickly write and ship code from a web browser. The start-up has raised a $4.5 million round of initial funding led by Andreessen ...
You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Rosalie Chan Every time Rosalie publishes a story, you’ll get an alert straight to your inbox!
Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
Replimune Group, Inc. (NASDAQ:REPL) stock plunged on Tuesday after a U.S. Food and Drug Administration (FDA) update. The clinical stage biotechnology company received an FDA Complete Response Letter ...
) has been revised to $10.84 / share. This is an increase of 48.75% from the prior estimate of $7.29 dated September 27, 2025. The price target is an average of many targets provided by analysts. The ...
Zacks Investment Research on MSN
Wall Street analysts predict a 65.72% upside in Replimune Group (REPL): Here's what you should know
Shares of Replimune Group, Inc. (REPL) have gained 0.7% over the past four weeks to close the last trading session at $7.76, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results